J. Van DerPALEN

Publications (1)1.65 Total impact

• Article: Multicenter cohort study on treatment results and risk factors in stage II endometrial carcinoma

  J.J. JOBSEN, M.L.M. LYBEERT, E.M. Van DerSTEEN-BANASIK, A. SLOT, J. Van DerPALEN, L.N. TenCATE, A. SCHOLTEN, V. COEN, E.M.J. SCHUTTER, S. SIESLING
  [show abstract] [hide abstract]
  ABSTRACT: The aim of this study was to report outcome data and prognostic factors from a large cohort of pathologic stage II endometrioid type endometrial carcinoma. One hundred forty-two stage IIA–B patients were included. A central histopathologic review was performed. Follow-up ranged from 2 to 217 months with a median of 61 months. End points of the study were local and locoregional recurrence rates, distant metastasis–free survival (DMFS), disease-free survival (DFS), and disease-specific survival (DSS). The local failure rate was 5.1% for stage IIA patients and 10.8% for stage IIB patients. Grade was the only significant prognostic factor for local failure. With respect to DMFS, DFS, and DSS, grade 3 showed to be the most prominent prognostic factor in multivariate analyses. Lymphvascular space involvement combined with grades 3 and 2 and myometrial invasion greater than 0.5 also showed to be significant for DMFS and DFS. Our study showed grade 3 to be the most important single independent predictive factor for locoregional and distant recurrences in endometrial carcinoma stage II.
  International Journal of Gynecological Cancer 12/2007; 18(5):1071 - 1078. · 1.65 Impact Factor